VE303

The microbiome therapeutics landscape shows remarkable growth with over 140 companies actively developing 180+ pipeline drugs, spanning various disease areas and therapeutic approaches.

VE303, a defined bacterial consortium, significantly reduced the risk of recurrent Clostridioides difficile infection (rCDI) in a Phase 2 trial compared to placebo.

The liver cirrhosis treatment market is experiencing significant growth, driven by advancements in antiviral therapies and regenerative medicine. Over 30 companies are actively developing new treatments, with several promising therapies currently in clinical trials.

BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer.

Real-world data presented at ID Week 2024 confirms the continued efficacy and safety of Rebyota, a live biotherapeutic product, for recurrent Clostridioides difficile infection (rCDI) two years post-approval.